Related references
Note: Only part of the references are listed.Monitoring of clonal evolution of acute myeloid leukemia identifies the leukemia subtype, clinical outcome and potential new drug targets for post-remission strategies or relapse
Esther Onecha et al.
HAEMATOLOGICA (2021)
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia
Samantha Bruno et al.
FRONTIERS IN ONCOLOGY (2021)
Deletions in FLT-3 juxtamembrane domain define a new class of pathogenic mutations: case report and systematic analysis
David J. Young et al.
BLOOD ADVANCES (2021)
The mutational spectrum of FLT3 gene in acute lymphoblastic leukemia is different from acute myeloid leukemia
Yu Zhang et al.
CANCER GENE THERAPY (2020)
FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development
Hitoshi Kiyoi et al.
CANCER SCIENCE (2020)
Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition
Margarita M. Dzama et al.
BLOOD (2020)
Targeting FLT3 mutations in AML: review of current knowledge and evidence
Naval Daver et al.
LEUKEMIA (2019)
Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients
C. Roellig et al.
ANNALS OF ONCOLOGY (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Ordering of mutations in acute myeloid leukemia with partial tandem duplication of MLL (MLL-PTD)
Q-Y Sun et al.
LEUKEMIA (2017)
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
R. M. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia
Michael W. M. Kuhn et al.
CANCER DISCOVERY (2016)
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
Christoph Rollig et al.
LANCET ONCOLOGY (2015)
Rare FLT3 deletion mutants may provide additional treatment options to patients with AML: an approach to individualized medicine
N. Chatain et al.
LEUKEMIA (2015)
Hematopoietic cell transplantation in patients with intermediate and high-risk AML: results from the randomized Study Alliance Leukemia (SAL) AML 2003 trial
J. Schetelig et al.
LEUKEMIA (2015)
Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis
M. Port et al.
ANNALS OF HEMATOLOGY (2014)
Use of Sorafenib as an effective treatment in an AML patient carrying a new point mutation affecting the Juxtamembrane domain of FLT3
Joaquin Martinez-Lopez et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
A novel point mutation within the juxtamembrane domain of the flt3 gene in acute myeloid leukemia
Valentina Gianfelici et al.
ANNALS OF HEMATOLOGY (2011)
Cytarabine Dose of 36 g/m2 Compared With 12 g/m2 Within First Consolidation in Acute Myeloid Leukemia: Results of Patients Enrolled Onto the Prospective Randomized AML96 Study
Markus Schaich et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications
Shinichiro Takahashi
JOURNAL OF HEMATOLOGY & ONCOLOGY (2011)
MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment
M. C. Stubbs et al.
LEUKEMIA (2008)
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles
Stefan Froehling et al.
CANCER CELL (2007)
D-HPLC analysis of the entire FLT3 gene in MLL rearranged and hyperdiploid acute lymphoblastic leukemia
Ronald W. Stam et al.
HAEMATOLOGICA (2007)
Four novel point mutations in exons 12, 13, and 14 of the FLT3 gene
Meilani Syampurnawati et al.
LEUKEMIA RESEARCH (2007)
Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD
Jennifer L. Rocnik et al.
BLOOD (2006)
Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML
C Reindl et al.
BLOOD (2006)
Novel FLT3 point mutations within exon 14 found in patients with acute myeloid leukaemia
DL Stirewalt et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Share Paper
